-
Major Psychedelics Firm Is Studying Magic Mushrooms To Treat Meth Addiction
Friday, September 16, 2022 - 3:10pm | 308Life sciences company Revive Therapeutics Ltd. (OTCQB: RVVTF) is advancing its first Phase I/II clinical trial of oral psilocybin for methamphetamine use disorder treatment while also developing an oral psilocybin thin film strip product. Revive is currently studying psilocybin’s potential as...
-
Intradermal Ketamine Patch Completes Pre-Clinical Phase, Advances To Clinical Studies
Wednesday, September 7, 2022 - 6:29pm | 572PharmaTher Holdings (OTCQB: PHRRF), the biopharma company developing novel uses and delivery forms of ketamine for mental health treatments, has completed an IND-enabling pharmacokinetic and tolerability study of its ketamine patch, KETARX, in minipigs. KETARX consists of hydrogel-forming...